KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Net Cash Flow: 2009-2025

Historic Net Cash Flow for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Sep 2025 value amounting to $136.0 million.

  • Jazz Pharmaceuticals' Net Cash Flow fell 84.17% to $136.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$896.3 million, marking a year-over-year decrease of 201.85%. This contributed to the annual value of $908.2 million for FY2024, which is 45.62% up from last year.
  • According to the latest figures from Q3 2025, Jazz Pharmaceuticals' Net Cash Flow is $136.0 million, which was up 120.10% from -$676.7 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Net Cash Flow ranged from a high of $1.0 billion in Q1 2021 and a low of -$1.2 billion during Q2 2021.
  • In the last 3 years, Jazz Pharmaceuticals' Net Cash Flow had a median value of $114.4 million in 2023 and averaged $39.9 million.
  • Examining YoY changes over the last 5 years, Jazz Pharmaceuticals' Net Cash Flow showed a top increase of 1,495.57% in 2021 and a maximum decrease of 1,538.39% in 2021.
  • Jazz Pharmaceuticals' Net Cash Flow (Quarterly) stood at -$78.9 million in 2021, then soared by 147.11% to $37.2 million in 2022, then spiked by 353.98% to $168.8 million in 2023, then increased by 16.70% to $197.0 million in 2024, then tumbled by 84.17% to $136.0 million in 2025.
  • Its Net Cash Flow stands at $136.0 million for Q3 2025, versus -$676.7 million for Q2 2025 and -$552.6 million for Q1 2025.